Integra LifeSciences Holdings (IART)vsStryker Corporation (SYK)
IART
Integra LifeSciences Holdings
$16.99
-3.25%
HEALTHCARE · Cap: $1.22B
SYK
Stryker Corporation
$305.66
+2.15%
HEALTHCARE · Cap: $112.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 1437% more annual revenue ($25.27B vs $1.64B). SYK leads profitability with a 13.2% profit margin vs -30.1%. IART appears more attractively valued with a PEG of 0.71. SYK earns a higher WallStSmart Score of 59/100 (C).
IART
Buy52
out of 100
Grade: C-
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$81.09
Current Price
$16.99
$64.10 discount
Margin of Safety
-35.2%
Fair Value
$223.02
Current Price
$305.66
$82.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Large-cap with strong market position
Areas to Watch
2.4% revenue growth
0.4% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IART
The strongest argument for IART centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : IART
The primary concerns for IART are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.96 is elevated, increasing financial risk.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IART profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
IART carries more volatility with a beta of 1.08 — expect wider price swings.
SYK is growing revenue faster at 2.6% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (59/100 vs 52/100). IART offers better value entry with a 86.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Integra LifeSciences Holdings
HEALTHCARE · MEDICAL DEVICES · USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?